✦ LIBER ✦

The efficacy of extended treatment with pegylated interferon plus ribavirin in patients with HCV genotype 1 and slow virologic response in Japan

✍ Scribed by Tsugiko Oze; Naoki Hiramatsu; Takayuki Yakushijin; Kiyoshi Mochizuki; Kazuho Imanaka; Akira Yamada; Masahide Oshita; Akira Kaneko; Hideki Hagiwara; Eiji Mita; Toshifumi Ito; Toshihiko Nagase; Yoshiaki Inui; Taizo Hijioka; Shinji Tamura; Harumasa Yoshihara; Eijiro Hayashi; Yasuharu Imai; Michio Kato; Atsushi Hosui; Takuya Miyagi; Yuichi Yoshida; Hisashi Ishida; Tomohide Tatsumi; Shinichi Kiso; Tatsuya Kanto; Akinori Kasahara; Tetsuo Takehara; Norio Hayashi

Publisher: Springer Japan
Year: 2011
Tongue: English
Weight: 269 KB
Volume: 46
Category: Article
ISSN: 0944-1174
DOI: 10.1007/s00535-011-0403-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy of re-treatment with pegylated

Efficacy of re-treatment with pegylated interferon plus ribavirin combination therapy for patients with chronic hepatitis C in Japan

✍ Tsugiko Oze; Naoki Hiramatsu; Takayuki Yakushijin; Kiyoshi Mochizuki; Masahide O 📂 Article 📅 2011 🏛 Springer Japan 🌐 English ⚖ 297 KB

Pegylated interferon alpha-2b plus ribav

Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: The role of rapid and early virologic response

✍ Sanaa M. Kamal; Samer S. El Kamary; Michelle D. Shardell; Mohamed Hashem; Imad N 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 251 KB 👁 2 views

In patients chronically infected with hepatitis C virus (HCV) genotype 4, the optimum duration of therapy and the predictors of sustained virologic response (SVR) have not been adequately determined. In this study, 358 patients with chronic hepatitis C genotype 4 were randomly assigned to pegylated

Mutations in the interferon sensitivity

Mutations in the interferon sensitivity determining region and virological response to combination therapy with pegylated-interferon alpha 2b plus ribavirin in patients with chronic hepatitis C-1b infection

✍ Mina Nakagawa; Naoya Sakamoto; Mayumi Ueyama; Kaoru Mogushi; Satoshi Nagaie; Yas 📂 Article 📅 2010 🏛 Springer Japan 🌐 English ⚖ 266 KB

Virologic response rates of weight-based

Virologic response rates of weight-based taribavirin versus ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C

✍ Fred Poordad; Eric Lawitz; Mitchell L. Shiffman; Tarek Hassanein; Andrew J. Muir 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 265 KB 👁 1 views

Muir is a consultant for, is on the speakers' bureau of, and received grants from Merck. He received grants from Valeant. He is also a consultant for and received grants from Zynogenetics. Dr. Poordad is a consultant for and received grants from Valeant. Dr. Shiffman advises and received grants from

Ribavirin pharmacokinetics and interleuk

Ribavirin pharmacokinetics and interleukin 28B plus cytochrome P450 27B1 single-nucleotide polymorphisms as predictors of response to pegylated interferon/ribavirin treatment in patients infected with hepatitis C virus genotype 1/4

✍ Antonio D'Avolio; Alessia Ciancio; Marco Siccardi; Lorena Baietto; Marco Simiele 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 209 KB 👁 1 views

We read with great interest the recent report by Li et al. 1 analyzing the correlation between the clusters of differentiation 24 (CD24) polymorphism and risk of chronic hepatitis B virus (HBV) infection. In their study, the CD24 P170 T allele (thymidine at position 170) was correlated with a strong

A matched case-controlled study of 48 an

A matched case-controlled study of 48 and 72 weeks of peginterferon plus ribavirin combination therapy in patients infected with HCV genotype 1b in Japan: amino acid substitutions in HCV core region as predictor of sustained virological response

✍ Norio Akuta; Fumitaka Suzuki; Miharu Hirakawa; Yusuke Kawamura; Hiromi Yatsuji; 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 122 KB 👁 1 views

## Abstract Substitution of amino acid (aa) 70 and 91 in the core region of HCV genotype 1b is a useful pretreatment predictor of efficacy of 48‐week peginterferon (PEG‐IFN) plus ribavirin (RBV) therapy. Here, we determined the efficacy of 72‐week PEG‐IFN/RBV and the predictive factors to such ther